Patents by Inventor Gregory P. Lunstrum
Gregory P. Lunstrum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230349921Abstract: The present invention provides methods for determining bone growth velocity comprising: (a) measuring an amount of a collagen X marker in a sample obtained from a subject in need thereof; and (b) comparing the amount of collagen X marker measured in step (a) with a collagen X marker standard curve, wherein the amount of collagen X marker is measured using at least two reagents. In an embodiment, there is at least one capture reagent and at least one detection reagent. In a preferred embodiment for measuring CXM, the capture reagent is the aptamer SOMA1 and the detection reagent is the monoclonal antibody mAb X34. The present invention further provides methods for treating diseases, disorders or conditions comprising receiving an identification of an amount of CXM in a sample, wherein the amount of CXM has been identified using a combination of SOMA1 and mAb X34 as CXM-binding reagents, and administering a treatment in light of the amount of CXM in the sample.Type: ApplicationFiled: February 23, 2023Publication date: November 2, 2023Inventors: William A. Horton, Gregory P. Lunstrum, Ryan F. Coghlan, Jon A. Oberdorf
-
Publication number: 20220065870Abstract: The present invention provides methods for determining bone growth velocity comprising: (a) measuring an amount of a collagen X marker in a sample obtained from a subject in need thereof; and (b) comparing the amount of collagen X marker measured in step (a) with a collagen X marker standard curve, wherein the amount of collagen X marker is measured using at least two reagents. In an embodiment, there is at least one capture reagent and at least one detection reagent. In a preferred embodiment for measuring CXM, the capture reagent is the aptamer SOMA1 and the detection reagent is the monoclonal antibody mAb X34. The present invention further provides methods for treating diseases, disorders or conditions comprising receiving an identification of an amount of CXM in a sample, wherein the amount of CXM has been identified using a combination of SOMA1 and mAb X34 as CXM-binding reagents, and administering a treatment in light of the amount of CXM in the sample.Type: ApplicationFiled: November 11, 2021Publication date: March 3, 2022Inventors: William A. Horton, Gregory P. Lunstrum, Ryan F. Coghlan, Jon A. Oberdorf
-
Publication number: 20210223263Abstract: The present invention provides methods for determining bone growth velocity comprising: (a) measuring an amount of a collagen X marker in a sample obtained from a subject in need thereof; and (b) comparing the amount of collagen X marker measured in step (a) with a collagen X marker standard curve, wherein the amount of collagen X marker is measured using at least two reagents. In an embodiment, there is at least one capture reagent and at least one detection reagent. In a preferred embodiment for measuring CXM, the capture reagent is the aptamer SOMA1 and the detection reagent is the monoclonal antibody mAb X34. The present invention further provides methods for treating diseases, disorders or conditions comprising receiving an identification of an amount of CXM in a sample, wherein the amount of CXM has been identified using a combination of SOMA1 and mAb X34 as CXM-binding reagents, and administering a treatment in light of the amount of CXM in the sample.Type: ApplicationFiled: March 29, 2021Publication date: July 22, 2021Inventors: William A. Horton, Gregory P. Lunstrum, Ryan F. Coghlan, Jon A. Oberdorf
-
Publication number: 20200378990Abstract: The present invention provides methods for determining bone growth velocity comprising: (a) measuring an amount of a collagen X marker in a sample obtained from a subject in need thereof; and (b) comparing the amount of collagen X marker measured in step (a) with a collagen X marker standard curve, wherein the amount of collagen X marker is measured using at least two reagents. In an embodiment, there is at least one capture reagent and at least one detection reagent. In a preferred embodiment for measuring CXM, the capture reagent is the aptamer SOMA1 and the detection reagent is the monoclonal antibody mAb X34. The present invention further provides methods for treating diseases, disorders or conditions comprising receiving an identification of an amount of CXM in a sample, wherein the amount of CXM has been identified using a combination of SOMA1 and mAb X34 as CXM-binding reagents, and administering a treatment in light of the amount of CXM in the sample.Type: ApplicationFiled: August 11, 2020Publication date: December 3, 2020Inventors: William A. Horton, Gregory P. Lunstrum, Ryan F. Coghlan, Jon A. Oberdorf
-
Publication number: 20180267061Abstract: The present invention provides methods for determining bone growth velocity comprising: (a) measuring an amount of a collagen X marker in a sample obtained from a subject in need thereof; and (b) comparing the amount of collagen X marker measured in step (a) with a collagen X marker standard curve, wherein the amount of collagen X marker is measured using at least two reagents. In an embodiment, there is at least one capture reagent and at least one detection reagent. In a preferred embodiment for measuring CXM, the capture reagent is the aptamer SOMA1 and the detection reagent is the monoclonal antibody mAb X34. The present invention further provides methods for treating diseases, disorders or conditions comprising receiving an identification of an amount of CXM in a sample, wherein the amount of CXM has been identified using a combination of SOMA1 and mAb X34 as CXM-binding reagents, and administering a treatment in light of the amount of CXM in the sample.Type: ApplicationFiled: March 8, 2018Publication date: September 20, 2018Inventors: William A. Horton, Gregory P. Lunstrum, Ryan F. Coghlan, Jon A. Oberdorf
-
Patent number: 6133236Abstract: Improving adhesion of epidermis to an underlying dermal substrate including the step of providing an amount of purified kalinin between the epidermis and dermal substrate wherein the kalinin provides adhesion between the human dermis and epidermis wherein said kalinin is a trimeric molecule having the following three nonidentical chains: a chain which includes the BM165 epitope, either a 155 kilodalton chain or a 105 kilodalton chain, and a 140 kilodalton chain.Type: GrantFiled: March 12, 1997Date of Patent: October 17, 2000Assignee: Oregon Health Sciences UniversityInventors: Robert E. Burgeson, Gregory P. Lunstrum, Patricia Rouselle, Douglas R. Keene, M. Peter Marinkovich
-
Patent number: 5770562Abstract: The isolated proteins kalinin and k-laminin are disclosed to provide adhesion between epidermal keratinocytes and the underlying dermis. Purified kalinin localizes to the anchoring filaments of basement membranes of human subepithelial skin, trachea, esophagus, cornea and amnion when such areas are probed with BM165 monoclonal antibody after localization. The protein has a molecular weight of approximately 410-495 kDa and exists in a cell-associated form (about 495 kDa) and two medium-associated forms (about 460 and 410 kDa, respectively). The BM165 epitope is located on the 165-kDa and 200 kDa subunits. Kalinin has a rotary-shadow image revealing an asymmetric rod 107-nm long having two globules at a first end and a single globule at an opposing end. The k-laminin adhesion molecule is an isolated heterotrimeric laminin variant that has a molecular weight of about 650 kDa and separates on western blots into first and second fragments that are similar to the B1 and B2 fragments of laminin.Type: GrantFiled: June 6, 1995Date of Patent: June 23, 1998Assignee: Oregon Health Sciences UniversityInventors: Robert E. Burgeson, Gregory P. Lunstrum, Patricia Rousselle, Douglas R. Keene, M. Peter Marinkovich
-
Patent number: 5352668Abstract: A purified protein kalinin is disclosed that provides adhesion between epidermal keratinocytes and the underlying dermis. Purified kalinin localizes to the anchoring filaments of basement membranes or human subepithelial skin, trachea, esophagus, cornea and amnion when such areas are probed with BM165 monoclonal antibody after localization. The protein has a molecular weight of approximately 400-460 kDa and exists in a cell-associated form (about 460 kDa) and two medium-associated forms (about 440 and 400 kDa, respectively). The cell-associated form comprises a 200-, a 155- and a 140-kDa subunit, all normally held together by disulflde bonds. The cell-associated form is subjected to extracellular processing to produce the two medium-associated forms, wherein, in the 440-kDa form, the 200-kDa subunit has been processed to a 165-kDa subunit and, in the 400-kDa form, the 155-kDa subunit has been processed to a 105-KDa subunit. The BM165 epitope is located on the 165-kDa subunit.Type: GrantFiled: August 28, 1992Date of Patent: October 4, 1994Assignee: The State of Oregon Acting By and Through The State Board of Higher Education on Behalf of Oregon Health Sciences UniversityInventors: Robnert E. Burgeson, Gregory P. Lunstrum, Patricia Rousselle, Douglas R. Keene, M. Peter Marinkovich